BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21221637)

  • 1. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma.
    Kobayashi Y; Miura K; Hojo A; Hatta Y; Tanaka T; Kurita D; Iriyama N; Kobayashi S; Takeuchi J
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1079-84. PubMed ID: 21221637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
    Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
    Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
    Çağlayan Ç; Goldstein JS; Ayer T; Rai A; Flowers CR
    Cancer; 2019 Jun; 125(11):1837-1847. PubMed ID: 30707765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Yamamoto M; Suzuki I; Saitou K; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Satoh S; Tajima K
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2995-3002. PubMed ID: 32524293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.
    Chihara D; Westin JR; Oki Y; Ahmed MA; Do B; Fayad LE; Hagemeister FB; Romaguera JE; Fanale MA; Lee HJ; Turturro F; Samaniego F; Neelapu SS; Rodriguez MA; Fowler NH; Wang M; Davis RE; Nastoupil LJ
    Cancer; 2016 Oct; 122(20):3145-3151. PubMed ID: 27351173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of clinical characteristics, treatment and survival of elderly patients with large diffuse B-cell lymphoma].
    Li CY; Yang P; Dong F; Tian L; Wan W; Zhao W; Li QH; Pang M; Zhen JF; Jing HM
    Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3296-3302. PubMed ID: 33202490
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma.
    Saygin C; Jia X; Hill B; Dean R; Pohlman B; Smith MR; Jagadeesh D
    Am J Hematol; 2017 Oct; 92(10):989-996. PubMed ID: 28612386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 11. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
    Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
    Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
    Miura K; Konishi J; Miyake T; Makita M; Hojo A; Masaki Y; Uno M; Ozaki J; Yoshida C; Niiya D; Kitazume K; Maeda Y; Takizawa J; Sakai R; Yano T; Yamamoto K; Sunami K; Hiramatsu Y; Aoyama K; Tsujimura H; Murakami J; Hatta Y; Kanno M
    Oncologist; 2017 May; 22(5):554-560. PubMed ID: 28408622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
    Advani RH; Chen H; Habermann TM; Morrison VA; Weller EA; Fisher RI; Peterson BA; Gascoyne RD; Horning SJ; ; ;
    Br J Haematol; 2010 Oct; 151(2):143-51. PubMed ID: 20735398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Berry B; Chhanabhai M; Fitzgerald C; Gill K; Hoskins P; Klasa R; Savage KJ; Shenkier T; Sutherland J; Gascoyne RD; Connors JM
    Blood; 2007 Mar; 109(5):1857-61. PubMed ID: 17105812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of
    Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
    Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.
    Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS
    Ann Hematol; 2012 Sep; 91(9):1383-91. PubMed ID: 22526364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.